Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
South Korea has the highest incidence of gastric cancer worldwide and Helicobacter pylori
infection is still prevalent. Clarithromycin-containing triple therapy is still the primary
therapy approved by the Korean government. However, studies of antibiotic resistance has
shown that regional resistance pattern to antibiotics such as clarithromycin, metronidazole,
or quinolone. Recent study in Korea has shown that modified-quadruple therapy has comparable
eradication rate to concomitant therapy. However, there has been no comparable study of
modified-quadruple therapy with bismuth-containing quadruple therapy. The aim of this study
is to compare the eradication rate of modified-quadruple therapy and bismuth-containing
quadruple therapy with presenting phenotypic and genotypic antibiotic resistance profile.